Hemispherx Biopharma Quote - HEB

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

1.80

Bid

Ask

Volume

0.00 Day's Range 0.00

0.00 52 Week Range 0.00

Market Cap

87.916M

Previous Close

1.80

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

Shares Outstanding

48,842,000

Dividend Yield

PE Ratio

-3.04

Earnings Per Share (EPS)

-0.59

Revenue

202k

Net Profit

-28.96M

Hemispherx Biopharma Inc is a US-based specialty pharmaceutical company. It is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune-based disorders. The products of the firm are Alferon N Injection and the e... Hemispherx Biopharma Inc is a US-based specialty pharmaceutical company. It is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune-based disorders. The products of the firm are Alferon N Injection and the experimental therapeutic Ampligen. Alferon N Injection is approved for a category of STD infection, and Ampligen represents a RNA being developed for viral diseases and disorders of the immune system. The sales revenue of the company is derived from the United States. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.aimimmuno.com

Headquarters

Wilmington, Delaware, USA

Founded

Hemispherx Biopharma, Inc. Changes Name to AIM ImmunoTech Inc. Reflecting Ampligen’s® Immuno Modulation Progress in Ongoin...

OCALA, Fla., Aug. 23, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-tech company focused on the research and development of immunological agents to treat...

Hemispherx Issues 2019 Second Quarter Report Citing Strong Steady Progress in Cancer Clinical Trials

OCALA, Fla., Aug. 15, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple...

Hemispherx Reports Positive Safety and Survival Data in Phase 1 Stage 4 Ovarian Cancer Clinical Study Using Ampligen®

OCALA, Fla., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE American: HEB) announced today that the University of Pittsburgh Medical Center (UPMC) has issued a final report...

Hemispherx Secures Corrections from Two Stock News Organizations Related to Their Inaccurate Reporting of an Equity Distribut...

OCALA, Fla., Aug. 02, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE American: HEB) recently demanded and received retractions and corrections in two cases of inaccurate reporting due to AI...

Hemispherx Biopharma CFO Adam Pascale Announces Retirement

OCALA, Fla., June 28, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) announced today that Adam Pascale is retiring from the position of Chief Financial Officer after...

Hemispherx Biopharma Issues Clinical Update for Ampligen Immuno-oncology Program

OCALA, Fla., June 17, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma Inc. (NYSE American: HEB) issued its quarterly update on the progress of its ongoing clinical trials evaluating Ampligen’s...

Hemispherx Biopharma Announces First Patient Treated in Phase 2 Ovarian Cancer Clinical Trial Evaluating Ampligen in Combinat...

OCALA, Fla., June 12, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx Biopharma Inc. announced today that the first patient has been treated in the Phase 2 recurrent ovarian cancer...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

HEB - Frequently Asked Questions (FAQ)

What is the current Hemispherx Biopharma share price?

The current share price of Hemispherx Biopharma is US$ 1.80

How many Hemispherx Biopharma shares are in issue?

Hemispherx Biopharma has 48,842,000 shares in issue

What is the market cap of Hemispherx Biopharma?

The market capitalisation of Hemispherx Biopharma is USD 87.92M

What is the 1 year trading range for Hemispherx Biopharma share price?

Hemispherx Biopharma has traded in the range of US$ 0.00 to US$ 0.00 during the past year

What is the PE ratio of Hemispherx Biopharma?

The price to earnings ratio of Hemispherx Biopharma is -3.04

What is the cash to sales ratio of Hemispherx Biopharma?

The cash to sales ratio of Hemispherx Biopharma is 439.02

What is the reporting currency for Hemispherx Biopharma?

Hemispherx Biopharma reports financial results in USD

What is the latest annual turnover for Hemispherx Biopharma?

The latest annual turnover of Hemispherx Biopharma is USD 202k

What is the latest annual profit for Hemispherx Biopharma?

The latest annual profit of Hemispherx Biopharma is USD -28.96M

What is the registered address of Hemispherx Biopharma?

The registered address for Hemispherx Biopharma is 251 LITTLE FALLS DRIVE, NEW CASTLE, WILMINGTON, DELAWARE, 19808

What is the Hemispherx Biopharma website address?

The website address for Hemispherx Biopharma is www.aimimmuno.com

Which industry sector does Hemispherx Biopharma operate in?

Hemispherx Biopharma operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
CKXCKX Lands Inc	US$ 18.00 (53.32%)	94
EONREON Resources Inc	US$ 1.5095 (47.99%)	39.48M
TPETTrio Petroleum Corp	US$ 2.49 (39.89%)	11.21M
LMBODirexion Daily Crypto Industry Bull 2x Shares	US$ 33.97 (26.32%)	313
BHMBluerock Homes Trust Inc	US$ 14.38 (15.97%)	1
GLUGabelli Global Utility and Income Trust	US$ 8.01 (-46.28%)	1
EIMEaton Vance Municipal Bond Fund	US$ 6.01 (-40.96%)	1
SVTServotronics Inc	US$ 7.01 (-33.75%)	3
GENCGencor Industries Inc	US$ 13.20 (-20.34%)	14
ETUT Rex 2X Long Ether Daily Target ETF	US$ 36.00 (-13.32%)	138
EONREON Resources Inc	US$ 1.5095 (47.99%)	39.48M
TPETTrio Petroleum Corp	US$ 2.49 (39.89%)	11.21M
ETHU2x Ether ETF	US$ 7.30 (-11.94%)	4.24M
MSTUT Rex 2X Long MSTR Daily Target ETF	US$ 13.10 (-0.23%)	4.13M
SOXLDirexion Daily Semiconductor Bull 3X Shares	US$ 33.36 (2.68%)	2.68M